Rifampicin (RIF) Monotherapy (4 months for Latent TB Infection)

Treatment for Drug-susceptible tuberculosis

Typical Dosage: Rifampicin 600mg daily

Effectiveness
77%
Safety Score
68%
Clinical Trials
25
Participants
20K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
68
DangerousModerateSafe
Treatment Details
Dosage Range
Rifampicin 600mg daily
Time to Effect
Prevention initiated within weeks, protective effect over years
Treatment Duration
4 months
Evidence Quality
HIGH
Number Needed to Treat (NNT)
15(Treat 15 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
150(Treat 150 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$120
Monitoring:$150
Side Effect Mgmt:$50
Total Annual:$320
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENT
ICER
$25,000/QALY
QALYs Gained
0.1
Comparison vs Isoniazid (INH) Monotherapy (9 months)
Cost Difference
$-5/year
Less expensive
QALY Difference
0.00 QALYs
Same outcomes
Dominance
DOMINATESBetter + cheaper
Rifampicin (RIF) Monotherapy (4 months for Latent TB Infection) Outcomes

for Drug-susceptible tuberculosis

Efficacy Outcomes
Overall Effectiveness
+77%
Common Side Effects
GI upset
+10%
Orange/red discoloration of body fluids
+100%
Hepatotoxicity
+3%
Rash
+5%

Sources:

nih.gov
researchgate.net
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

FIX IT
Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov